Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: lung

Experts Discuss Guidelines for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease

Ruth Jessen Hickman, MD  |  March 6, 2025

Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceSjögren’s DiseaseSystemic Sclerosis Tagged with:Interstitial Lung Diseaseinterstitial lung disease (ILD)

Considerations for Lung Transplants in Patients with SARD-ILD

Ruth Jessen Hickman, MD  |  December 2, 2024

At this ACR Convergence 2024 session, Sonye Danoff, MD, PhD, discussed many factors that need to be considered before referring patients with SARD-ILD for lung transplantation.

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2024ILDinterstitial lung disease (ILD)lung transplantlungsorgan transplantSARD-ILDsystemic autoimmune rheumatic disease-related interstitial lung disease

Lung Cancer in RA & RA-ILD

Arthritis & Rheumatology  |  November 25, 2024

Brooks et al. evaluated the risk of lung cancer in patients with rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD) compared with the risk in matched controls without RA or RA-ILD. Understanding whether RA predisposes someone to lung cancer and whether patients with RA-ILD represent a uniquely high-risk group could inform cancer-screening strategies.

Filed under:ConditionsRheumatoid Arthritis Tagged with:Arthritis & RheumatologyILDinterstitial lung disease (ILD)Rheumatiod arthritis

ADOBE STOCK | Feodora

The Great Pediatric Debate 2024: Cessation or Continuation of Biologics in sJIA Lung Disease?

Ruth Jessen Hickman, MD  |  November 23, 2024

Washington D.C.—At a Sunday, Nov. 17, Pediatrics Great Debate session of ACR Convergence, speakers argued whether patients with systemic juvenile idiopathic arthritis (sJIA) should continue their interleukin (IL) 1/IL-6 biologics if lung disease is suspected. Randy Q. Cron, MD, PhD, the director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham,…

Filed under:ACR ConvergenceConditionsPediatric Conditions Tagged with:ACR Convergence 2024sJIAsJIA-associated lung disease

Catch Your Breath: Understanding Interstitial Lung Disease in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  November 19, 2024

The session highlighted the importance of correctly identifying and treating patients with RA-ILD early in their disease course.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RAILDInterstitial Lung Disease

Case Report: Diaphragm Ultrasound Reveals Shrinking Lung Syndrome

Mery Deeb, MD, Taro Minami, MD, Michael Stanchina, MD, Elias Jabbour, MD, & Jan Karczewski, MD  |  July 9, 2024

Shrinking lung syndrome (SLS) is a rare cause of dyspnea that has been most commonly described in patients with systemic lupus erythematosus (SLE), but is also found in systemic sclerosis, Sjögren’s disease and rheumatoid arthritis. Shrinking lung syndrome is characterized by a restrictive pattern on lung spirometry, despite normal lung parenchyma, and an elevated diaphragm.1…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportdyspneashrinking lung syndromeSLE Resource CenterUltrasound

Tips from a Cardiothoracic Radiologist: Interstitial Lung Disease & Radiology for the Rheumatologist

Samantha C. Shapiro, MD  |  June 17, 2022

Due to its array of radiographic patterns, interstitial lung disease can be challenging to diagnose and treat. Adam Guttentag, MD, a cardiothoracic radiologist, shared tips for ordering and interpreting chest computed tomography.

Filed under:ConditionsMeeting ReportsOther ACR meetings Tagged with:ACR Education Exchangecomputed tomographyconnective tissue diseaseCT scanCTD-ILDILDinterstitial lung disease (ILD)lungsRadiologistVasculitis

Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

Samantha C. Shapiro, MD  |  June 15, 2022

No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

Filed under:ConditionsSystemic Sclerosis Tagged with:ILDinterstitial lung disease (ILD)lungsnintedanibSclerodermaSSc-ILDsystemic sclerosis (SSc)tocilizumab

Advances in Connective Tissue Disease-Associated Interstitial Lung Disease

Jason Liebowitz, MD, FACR  |  December 1, 2021

ACR Convergence 2021—The past year has been an exciting time for researchers and clinicians focused on the topic of connective tissue disease-associated interstitial lung disease (CTD-ILD), with advances in our understanding of these disorders and newly approved medications for their treatment. At the ACR Convergence 2021 annual Review Course, Kristin Highland, MD, MSCR, director of…

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Sclerosis Tagged with:ACR Convergence 2021connective tissue diseaseinterstitial lung disease (ILD)nintedanib

Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

Lara C. Pullen, PhD  |  September 22, 2021

Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.

Filed under:Conditions Tagged with:interstitial lung disease (ILD)systemic sclerosis (SSc)systemic sclerosis-associated ILDtocilizumab

  • 1
  • 2
  • 3
  • …
  • 72
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences